|
Age (median, year)
|
48
|
%
|
33–78
|
|
Mutations
| | | |
|
-BRCA1
|
288
|
61.1
| |
|
-BRCA2
|
126
|
26.8
| |
|
-BRCA1 and BRCA2
|
2
|
0.4
| |
|
-HBOC
|
55
|
11.7
| |
|
CA-125 preoperative (n)
|
466
| | |
|
-median (U/ml)
|
14.0
| |
4.0–93.0
|
|
-elevated CA125 (>35 U/ml) (n)
|
10
|
2.1
| |
|
Surgical technique (n)
|
471
| | |
|
-laparoscopy
|
430
|
91.3
| |
|
-laparotomy
|
37
|
7.9
| |
|
-vaginal
|
3
|
0.6
| |
|
-combined with supravaginal uterus extirpation
|
1
|
0.2
| |
|
Documented complications (n)
|
444
|
94.3
| |
|
-no complications during surgery and/or postoperatively
|
416
|
93.7
| |
|
-complications
|
28
|
5.9
| |
|
-converted to laparotomy because of adhesions
|
10
| | |
|
-hematoma
|
10
| | |
|
-iatrogenic injury (intestine/ureter)
|
3
| | |
|
-incomplete removal of the ovaries
|
1
| | |
|
-not possible to remove ovaries because of adhesions
|
1
| | |
|
-other
|
3
| | |
|
Menopausal status (n)
|
447
| | |
|
-postmenopausal
|
187
|
41.8
| |
|
-because of hormonal breast cancer treatment
|
32
|
17.1
| |
|
-because of previous ovariectomy
|
8
|
4.3
| |
|
-premenopausal
|
241
|
53.9
| |
|
-perimenopausal
|
19
|
4.3
| |
|
-because of hormonal breast cancer treatment
|
10
|
52.6
| |
|
HRT in premenopausal women (n)
|
217
| | |
|
-postoperative usage of HRT
|
97
|
45.3
| |
|
Follow up (median, mo) (n = 375)
|
55.8
| |
0.6–169.0
|
|
-deceased in FU
|
19
|
5.1
| |
|
-age (median, year)
|
55.5
| |
43.1–72.0
|
|
-development of breast cancer in FU
|
57
|
12.1
| |
|
-development of PPC in FU
|
1
|
0.2
| |
|
-development of other malignancy
|
22
|
4.7
| |
|
Previous breast cancer (n)
|
195
|
41.4
| |
|
-age first breast cancer (median, year)
|
41.0
| |
24.7–64.0
|
|
Cytology
| | | |
|
PWC sample not available
|
191
|
40.6
| |
|
PWC sample available
|
280
|
59.4
| |
|
-PWC analyzable
|
257
|
91.8
| |
|
-PWC malignant
|
4
|
1.6
| |
|
-PWC atypical
|
1
|
0.4
| |
|
Ascites sample reported
|
21
|
4.5
| |
|
-Ascites sample available for analysis
|
13
|
61.9
| |
|
-ascites malignant
|
0
|
0
| |
|
-ascites atypical
|
0
|
0
| |
|
Histology RRSO specimen
| | | |
|
Ovarian (n)
|
469
| | |
|
-benign
|
399
|
85.1
| |
|
-primary serous adenocarcinoma
|
4
|
0.9
| |
|
-granulosa cell tumor
|
1
|
0.2
| |
|
-borderline tumor
|
1
|
0.2
| |
|
-stromal hyperplasia
|
2
|
0.4
| |
|
-mature cystic teratoma (benign)
|
4
|
0.9
| |
|
-cyst (serous/mucinous/simple/endometriosis/Theca lutein/corpus luteum)
|
43
|
9.2
| |
|
-cystadenoma/cystadenofibroma
|
15
|
3.2
| |
|
Fallopian tube (n)
|
470
| | |
|
-benign
|
433
|
92.1
| |
|
-adenocarcinoma
|
5
|
0.6
| |
|
-serous large cell carcinoma
|
1
|
0.2
| |
|
-benign mesothelial hyperplasia
|
1
|
0.2
| |
|
-epithelial dysplasia
|
1
|
0.2
| |
|
-cystadenoma/cystadenofibroma
|
9
|
1.9
| |
|
-endometriosis
|
7
|
1.5
| |
|
-endosalpingiosis
|
13
|
2.8
| |
